Physician profile

Heather Bell

Infectious Disease · Tulsa, OK

NPI 1881758563

$1,732.97

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$271.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Kci USA, INC. $366.47 2019
Viiv Healthcare Company $232.83 2019
Smith+Nephew, INC. $227.62 2019
Gilead Sciences, INC. $193.37 2021-2023
Osiris Therapeutics INC. $192.24 2019
Organogenesis INC. $138.60 2019-2023 Puraply
Insmed, INC. $128.75 2022
Kerecis Limited $110.76 2021
Next Science LLC $58.59 2023 Blastx, Surgx, Xperience
Abbvie INC. $44.33 2023 Dalvance
Emd Serono, INC. $20.03 2022
Ibsa Pharma INC. $19.38 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Heather Bell

$1,732.97

in general payments reported 2019-2025

Years
2019-2023
Top company
Kci USA, INC.

https://glasscript.com/doctor/39771/heather-bell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.